Introduction
============

The human colonic microflora ecosystem, its metabolic functions, and its colonization resistance are vital for the well-being of the host, production of vital metabolites, and prevention of infection ([@b36-tcrm-4-1343]; [@b93-tcrm-4-1343], [@b94-tcrm-4-1343]). Various enzymes in the microbial ecosystem are implicated in deconjugation, reduction, and other biochemical activities, which result in altered bioavailability, activation, or detoxi-fication of different molecules, including those drug metabolites released by the liver via bile ducts ([@b88-tcrm-4-1343]). *In vitro* models have shown that change in population composition of the human intestinal microflora is concurrent with reduced colonization resistance ([@b98-tcrm-4-1343]). Furthermore, the microbial community may have an unknown influence on the immune system ([@b96-tcrm-4-1343]). The colonic microflora appears to stimulate the host immune system to respond rapidly to pathogen challenges ([@b13-tcrm-4-1343]). Although the cells of the intestinal tract coexist with the normal commensal microflora, they recognize and clear invading pathogens before returning to homeostasis with the commensal bacteria. The roles and influences of different commensal bacteria vary. Host responses to the effects of commensal bacteria are genetically determined ([@b83-tcrm-4-1343]). In patients with inflammatory bowel syndrome, the mucosal immune system shows an abnormal reaction to commensal bacteria in genetically susceptible individuals. The use of therapeutic agents to affect the bacterial population may result in microbial imbalances that affect health and cause disease. Based on clinical and epidemiological studies, it has been hypothesized that both the therapeutic use of antibiotics and the typical diets in industrialized countries may disrupt normal microbiota-mediated mechanisms of immunological tolerance in the mucosa, which also may result in an increase in allergic airway disease ([@b78-tcrm-4-1343]). In the following sections, other effects of the clinical usage of antimicrobial agents on intestinal microflora will be discussed.

Disturbance of the ecosystem
============================

Although the colonic ecosystem is generally stable, it can be disturbed by the administration of antimicrobial agents for treatment or prophylaxis ([@b80-tcrm-4-1343]). The colonic bacteria are exposed to antimicrobial agents whether they are administered orally or through injection via the circulation ([@b36-tcrm-4-1343]). This exposure may occur through incomplete absorption of antimicrobial agents administered orally, through exposure to antimicrobial agents in secretions by the salivary glands or intestinal mucosa or in bile from the liver ([@b69-tcrm-4-1343], [@b71-tcrm-4-1343]; [@b11-tcrm-4-1343]).

The extent of changes that occur in the intestinal micro-flora community as the result of administration of antimicrobial agents depends on the antibacterial spectrum and its concentration in the luminal content ([@b69-tcrm-4-1343], [@b71-tcrm-4-1343]). Antibiotics given orally that are absorbed in the upper part of the small intestine differ in their effects from those that are poorly absorbed. Parenteral antimicrobial agents, whether secreted in the bile or from mucosa, also affect susceptible bacterial populations ([@b67-tcrm-4-1343]; [@b36-tcrm-4-1343]). Exposure of the colonic ecosystem to antimicrobial agents may result in a shift in population of different components as the result of suppression or elimination of some microorganisms, overgrowth by microorganisms not susceptible to these agents, and establishment of antimicrobial-resistant members that normally are excluded ([@b61-tcrm-4-1343]).

Effect of commensal microorganisms on colonization
==================================================

Several factors contribute to the prevention of colonization by non-commensal microorganisms, among which are competition for nutrients, competition for attachment, and production of volatile fatty acids ([@b71-tcrm-4-1343]). Volatile fatty acids produced by anaerobic bacteria are toxic to some other species, especially enterobacteria. Production of bacteriocins by enterobacteria, streptococci, and anaerobic bacteria also limits bacterial overgrowth.

Development of antimicrobial-resistant bacteria
===============================================

Another consequence of exposure to antibiotics that may have lasting effects is the emergence of antimicrobial-resistant bacteria that may cause problems in the long run ([@b67-tcrm-4-1343]). These organisms may be transmitted to different sites within the host, where they may cause infection, and to other hosts ([@b71-tcrm-4-1343]; [@b37-tcrm-4-1343]). An example is urinary tract infection caused by antimicrobial-resistant *Escherichia coli* ([@b99-tcrm-4-1343]; [@b37-tcrm-4-1343]).

A multicenter susceptibility survey ([@b4-tcrm-4-1343]) has shown changes in the patterns of resistance among anaerobic bacteria to different antibiotics. Antibiotic resistance in anaerobic bacteria now is known for β-lactams, clindamycin, macrolides, tetracyclines, fluoroquinolones, and nitroimidazole ([@b62-tcrm-4-1343]). Methicillin-resistant *Staphylococcus aureus* (MRSA) strains have been isolated from children in an outpatient clinic who had microbial imbalances of the large intestine resulting from antibiotic use ([@b59-tcrm-4-1343]).

Induction of enzymes in the colonic bacteria that make antimicrobial agents ineffective is another side effect of antimicrobial agents ([@b40-tcrm-4-1343]). Administration of β-lactams has resulted in increased levels of β-lactamases in the normal intestinal microflora ([@b39-tcrm-4-1343]). Induction of β-lactamases in some aerobic and anaerobic bacteria by cefoxitin has been reported. However, since feces appear to inhibit the induction of β-lactamases, [@b90-tcrm-4-1343] attribute increases in β-lactamases to the selection of "stably derepressed mutants" rather than to β-lactamase induction.

Fungal infections
=================

Another problem that may arise as the result of antibiotic treatment is fungal acquisition ([@b58-tcrm-4-1343]). Fungal overgrowth has been observed, specifically after treatment with antibiotics that reduce the population of anaerobic bacteria, in experimental animals, healthy individuals, and neutropenic patients ([@b51-tcrm-4-1343]; [@b58-tcrm-4-1343]; [@b82-tcrm-4-1343]). [@b58-tcrm-4-1343] conclude, "Preservation of the anaerobic flora appears critical in the prevention of fungal acquisition in neutropenic patients." Fungal infections may cause serious problems in immuno-compromised patients, producing disseminated infections in various sites that could result in severe complications ([@b41-tcrm-4-1343]).

[@b52-tcrm-4-1343] used *Candida albicans* to challenge antibiotic-treated and untreated mice and found an association of the fungus with the intestinal epithelia of antibiotic-treated mice but not with those of the control mice that had indigenous bacterial flora. In the treated mice, some of the fungal cells penetrated deep into the mucosa of the intestinal tract, but most of them were associated with the cecal mucosa.

Effects on bacterial pathogenicity
==================================

Antimicrobial agents, in addition to limiting the effectiveness of the colonization barrier by disturbing the normal intestinal microbiota, may also affect the pathogenicity of certain bacteria. Fluoroquinolones have been shown to induce bacteriophages and enhance Shiga toxin production in *E. coli* O157:H7, which may increase the virulence of this strain ([@b100-tcrm-4-1343]). In our laboratory, one out of five gatifloxacin-resistant *Clostridium perfringens* strains also had enhanced production of phospholipase C and perfringolysin O ([@b85-tcrm-4-1343]). Subinhibitory concentrations of ampicillin and clindamycin may directly affect adherence of *Clostridium difficile* by increasing the expression of genes necessary for colonization ([@b24-tcrm-4-1343]). In an *in vitro* animal study, it was shown that subcutaneous administration of antibiotics that disrupt anaerobic flora facilitated the growth and toxin production of *C. difficile* in mouse cecal contents. Antibiotics that did not have major effects on anaerobic populations did not affect growth or toxin production ([@b84-tcrm-4-1343]). These findings justify the concerns of government regulatory agencies, the World Health Organization, and health care professionals about the use of antimicrobial agents in farm animals ([@b21-tcrm-4-1343]).

Other side effects
==================

The use of antimicrobial agents usually is accompanied by gastrointestinal upsets, especially antibiotic-associated diarrhea, which frequently is resolved shortly after discontinuance of the antimicrobial agent and the return of balance to the ecosystem ([@b67-tcrm-4-1343]). It occurs in 15%--25% of patients treated with antibiotics and its incidence differs with various antibiotics. It is caused by mild to severe disturbance of gut microflora; the mild cases may result from disturbances in carbohydrate or bile acid metabolism. Proliferation of pathogens as the result of this disturbance may cause severe cases of antibiotic-associated diarrhea ([@b89-tcrm-4-1343]).

In an immunocompromised host, or those weakened by surgery or advanced age, severe infections by opportunistic pathogens can occur. Potential pathogens, like *C. difficile* residing in the colon, may cause *C. difficile*-related antibiotic-associated diarrhea and/or pseudomembranous colitis ([@b8-tcrm-4-1343], [@b9-tcrm-4-1343]; [@b6-tcrm-4-1343]; [@b40-tcrm-4-1343]; [@b37-tcrm-4-1343]). [@b40-tcrm-4-1343] noted that, with the exception of vancomycin and parenterally administered aminoglycosides, most other antimicrobial agents have been implicated in *C. difficile* infections.

Systemic infections in immunocompromised patients, caused by normally innocuous microorganisms, have also been observed following antibiotic treatment. Superinfection, in which all major types of anaerobes have been involved, also has been associated with the use of antimicrobial agents. In general, antimicrobial-related complications are the result of suppression of the indigenous flora that prevent colonization and overgrowth by potential pathogens residing in the colon, which may cause diarrhea, colitis or other septic conditions ([@b40-tcrm-4-1343]).

Evaluation of the effect of antimicrobial agents on intestinal microflora
=========================================================================

The apparent consequences of exposure of the colonic micro-flora to antimicrobial agents have been measured by enumeration of bacterial species following clinical treatment of the patient or experimental exposure of volunteers to different antimicrobial agents ([@b67-tcrm-4-1343]). Evaluation of resistance patterns of anaerobic bacteria in saliva and feces of outpatients and hospitalized patients, regardless of treatment with antibiotics, has shown an association among the relative numbers of antibiotic-resistant anaerobic bacteria, hospitalization, and antibiotic treatment. The number of resistant strains is correlated with the duration of antibiotic treatment ([@b92-tcrm-4-1343]).

In numerous studies, scientists have evaluated the effects of antimicrobial agents on colonic bacteria by administering the antibiotics to their subjects and measuring their effects on the populations of various bacterial genera. All major classes of antimicrobial agents have been studied. Most of this work has been performed by Carl Nord's laboratory at Karolinska University Hospital in Stockholm, Sweden, and several reviews have been written ([@b69-tcrm-4-1343], [@b71-tcrm-4-1343], [@b72-tcrm-4-1343]; [@b67-tcrm-4-1343]; [@b61-tcrm-4-1343]; [@b36-tcrm-4-1343]; [@b93-tcrm-4-1343]). Fecal specimens, which have generally been accepted as representative of the colonic microbiota, were cultured on non-selective and selective media. Different colony types were counted, isolated in pure culture, and identified to genus level. Their numbers were compared with the numbers of bacteria present from each genus before treatment to measure the effect of the antibiotic in decreasing the number of bacteria or allowing the increase, overgrowth or proliferation of others. All new colonizing bacteria were tested for susceptibility to the antibiotics that had been administered ([@b76-tcrm-4-1343], [@b77-tcrm-4-1343]). The bacteria that were eliminated and those that overgrew other species were reported. The development of resistance among bacteria in the normal flora and overgrowth of microorganisms like yeasts, which are controlled by the normal microflora, were also detected. In most cases, the populations of certain bacterial genera decreased while the number of bacteria from other genera increased. This increase was accompanied either by an increase in resistant strains of bacteria or by overgrowth of fungi ([@b58-tcrm-4-1343]; [@b60-tcrm-4-1343]).

Rapid methods using DNA analysis also have been used to show the effects of antimicrobial agents on the human intestinal microflora. [@b23-tcrm-4-1343] isolated fecal DNA from volunteers after antibiotic treatment and amplified bacterial 16S rRNA genes by PCR with general primers, which were analyzed by temporal temperature-gradient gel electrophoresis. By comparing the patterns of dominant species with the patterns generated before treatment, they determined the effects of treatments on alteration of the microbiota.

As the widespread emergence of various antimicrobial-resistant bacteria has been problematic, and fatalities have resulted from the overgrowth of otherwise innocuous commensal microorganisms that do not respond to available antimicrobial agents, it appears timely to review the effects of these compounds on colonic microorganisms, with an emphasis on those that have not been covered in previous reviews.

β-Lactams
=========

β-Lactams are the oldest and the most widely prescribed class of antibiotics; the class includes penicillins, cephalosporins, monobactams, carbapenems, and β-lactamase inhibitors.

Penicillins
===========

The members of this group include phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin, azlocillin, temocillin, ticarcillin, pivampicillin, talampicillin, and bacampicillin.

Cephalosporins
==============

Most of these are semisynthetic compounds and are not susceptible to cleavage of the β-lactam ring by many β-lactamases. They include cefaloridine, cefazolin, cefaclor, cephrocile, cefbuperazone, cefuroxime, cefoxitin, cefotiam, cefotaxime, cefoperazone, ceftriaxone, ceftazidime, ceftiazox-ime, cefmenoxime, cefotetan, cephradine, and ceftibutan.

Monobactams
===========

The β-lactam ring in monobactams is alone and not fused to another ring. Aztreonam is an example; it usually is used in combination with other drugs.

Carbapenems
===========

As more and more bacteria develop resistance to β-lactam antimicrobial agents by producing various β-lactamases, efforts have been made to find drugs that are not affected by β-lactamases. The carbapenems includes imipenem, meropenem, ertapenem, faropenem, doripenem, panipenem, and betamipron. Imipenem is inactivated in the kidney by a dehydropeptidase; to prevent this, it is used in combination with cilastatin, an inhibitor of kidney dehydropeptidase ([@b15-tcrm-4-1343]; [@b73-tcrm-4-1343]). In addition to being resistant to β-lactamases, the carbapenems have broad antibacterial activity.

β-Lactamase inhibitors
======================

These compounds contain a β-lactam ring but have negligible antimicrobial activity. Because they bind to β-lactamases and prevent their attack on other β-lactams, they are co-administered with antimicrobial β-lactams.

Impact of treatment with β-lactams on the human intestinal microflora
=====================================================================

The impacts of different β-lactam antibiotics have been evaluated both in human volunteers and in patients undergoing treatment. Various studies have considered the effects of the penicillin group: ampicillin ([@b54-tcrm-4-1343]), ampicil-lin plus sulbactam ([@b49-tcrm-4-1343]), piperacillin ([@b50-tcrm-4-1343]), azlocillin ([@b63-tcrm-4-1343]), temocillin ([@b95-tcrm-4-1343]), and ticarcillin and clavulanic acid ([@b64-tcrm-4-1343]) ([Table 1](#t1-tcrm-4-1343){ref-type="table"}). All of them decreased the numbers of enterobacteria, enterococci, and anaerobic bacteria. Treatment with amoxicillin ([@b55-tcrm-4-1343]; [@b42-tcrm-4-1343]) resulted in suppression of the numbers of enterobacteria in some trials but increased their numbers in others ([@b19-tcrm-4-1343]). In some trials, overgrowth of *C. difficile* was observed after treatment with amoxicillin, with or without clavulanic acid ([@b19-tcrm-4-1343]; [@b57-tcrm-4-1343]). Overgrowth by bacteria or *Candida* after the administration of the above drugs was observed in some trials. Ticarcillin/clavulanic acid administration resulted in increases in enterococci. Phenoxymethylpenicillin did not have much effect ([@b1-tcrm-4-1343]).

Since β-lactams were the first antibiotics to be discovered, they have been frequently prescribed for treatment of various infections and many bacteria have developed resistance to them. The presence of β-lactamases in various bacteria has resulted in the frequent ineffectiveness of these drugs. To avoid development of resistance and to enhance potency of the drugs, other β-lactams have been developed and used in combinations with β-lactamase inhibitors or other drugs ([Table 2](#t2-tcrm-4-1343){ref-type="table"}).

Pivmecillinam
=============

[@b94-tcrm-4-1343] studied the impact of treatment with pivmecillinam on the intestinal microfloras of 15 individuals. They were treated for 7 days with 400 mg of pivmecillinam twice daily and then again 14 and 21 days after the start of administration. There was a decrease in the numbers of *E. coli* but no changes occurred in the anaerobic microflora.

Piperacillin/tazobactam
=======================

The effect of piperacillin on the colonic bacteria has been reviewed ([@b67-tcrm-4-1343]). The impact on colonic ecology of its use in combination with a β-lactamase inhibitor, tazobactam, has also been investigated ([@b65-tcrm-4-1343], [@b66-tcrm-4-1343]; [@b74-tcrm-4-1343]). The effect of a piperacillin/tazobactam combination (4/0.5 g) on patients with intraabdominal infections who were treated three times a day for 8 days was evaluated; there were decreases in the mean numbers of enterobacteria, enterococci, and anaerobes (bifidobacteria, eubacteria, lactobacilli, clostridia, and Gram-positive cocci). Anaerobic Gram-negative cocci and *Bacteroides* spp. were unaffected ([Table 2](#t2-tcrm-4-1343){ref-type="table"}). The number of bacteria returned to normal after treatment was stopped ([@b65-tcrm-4-1343], [@b66-tcrm-4-1343]).

Omeprazole and amoxicillin
==========================

A combination of omeprazole (20 mg, a proton pump inhibitor for eradication of *Helicobacter pylori*) and amoxicillin (1000 mg) twice daily for 14 days resulted in changes in the microflora of the intestinal tract, increases in the numbers of resistant enterobacteria, and an increase in β-lactamase production detected in fecal samples ([@b90-tcrm-4-1343]; [@b2-tcrm-4-1343]).

Omeprazole/amoxicillin/metronidazole combinations
=================================================

The effects of amoxicillin in combination with antimicrobial agents effective against anaerobes also have been studied. Metronidazole, which is used for the treatment of anaerobic and parasitic infections, is also used in the treatment of *H. pylori* in combination with other drugs. Treatment of patients with a combination of 20 mg omeprazole, 1 g amoxicillin, and 40 mg metronidazole for 7 days resulted in alteration of normal microflora and pronounced suppression of the anaerobic microflora. During treatments, some patients also were colonized by yeasts. The MIC values of those drugs for *Enterococcus* spp. and the Enterobacteriaceae increased ([@b2-tcrm-4-1343]).

Amoxicillin/clavulanic acid
===========================

Administration of 1000 mg of amoxicillin/clavulanic acid for 7 days to 12 healthy individuals (the same persons who had been treated with 600 mg linezolid for 7 days, with a washout period of 4 weeks between treatments) resulted in increases in the numbers of enterococci and *E. coli* and significant decreases in the numbers of anaerobes, including bifidobacteria, lactobacilli, and clostridia. *C. difficile* was isolated from three volunteers ([@b57-tcrm-4-1343]). The authors concluded that unlike linezolid, amoxicillin/clavulanic acid does not eliminate Gram-positive bacteria.

Ten volunteers who received 500 mg amoxicillin three times a day for 7 days were colonized with amoxicillin-resistant bacteria, mostly *E. coli*, *Klebsiella*, and *Enterobacter* ([@b19-tcrm-4-1343]). β-Lactamase activity was detected in the microfloras of six of the subjects.

Imipenem
========

[@b46-tcrm-4-1343] evaluated the effects of imipe-nem, both when used for treatment and for prophylaxis, on the intestinal microflora. Use of 0.5 or 1 g of imipenem four times daily for 4--11 days resulted in a decrease in numbers of enterobacteria, anaerobic cocci, and *Bacteroides* spp. during treatment. The microflora was restored to normal afterward. Patients receiving 0.5 or 1 g of imipenem for surgical prophylaxis, every 6 hours for 48 hours, had suppressed levels of staphylococci, streptococci, enterococci, entero-bacteria, anaerobic bacteria, cocci, bifidobacteria, eubacteria, lactobacilli, clostridia, fusobacteria, and *Bacteroides* spp. during treatment; the levels were normal afterward. Colonization by imipenem-resistant bacteria did not occur ([@b46-tcrm-4-1343], [@b47-tcrm-4-1343]).

Aztreonam with either tobramycin or cloxacillin
===============================================

[@b58-tcrm-4-1343] used different combinations of drugs to treat febrile neutropenic patients and compared the impacts on the microbial ecology. Combinations of aztreonam with either tobramycin (15 subjects) or cloxacillin (14 subjects) resulted in the eradication of enteric Gram-negative bacilli. These combinations also caused reduction of the numbers of fecal anaerobes, accompanied by a reduced concentration of short-chain fatty acids in fecal supernatants ([@b58-tcrm-4-1343]). Fungal proliferation occurred in 27% of subjects receiving aztreonam/tobramycin and 43% of subjects receiving aztreonam/cloxacillin. Moxalactam/tobramycin combination treatments of 15 patients had similar effects on reduction of anaerobes and fungal acquisition (81%) as the previous two combinations. All of the subjects were febrile neutropenic patients, so the authors concluded that maintaining the anaerobic flora was essential for the prevention of fungal acquisition in febrile neutropenic patients.

Meropenem
=========

Intravenous injection of 500 mg meropenem three times daily for 7 days in 10 patients resulted in decreases in the numbers of enterobacteria and streptococci and increases in the numbers of enterococci, clostridia, *Bacteroides* spp., and Gram-negative cocci. Other Gram-positive cocci and rods were not affected. Two weeks after termination of therapy, the intestinal micro-flora had returned to normal ([@b14-tcrm-4-1343]).

Ertapenem and ceftriaxone
=========================

Administration of either ertapenem (1 g per day) or ceftri-axone (2 g per day) to 10 healthy individuals for 7 days via injection resulted in a 4-log reduction in *E. coli* as well as a reduction of the anaerobic microflora, including lactobacilli, bifidobacteria, clostridia, and *Bacteroides* spp. There was a 4-log increase in the number of enterococci. Overgrowth of yeast was observed in both treatments, but in both cases the microflora returned to normal within 21--35 days after treatment had concluded ([@b82-tcrm-4-1343]).

Cephalosporins
==============

Various cephalosporins have major effects on the colonic microflora ([@b67-tcrm-4-1343]). Cefbuperazone ([@b45-tcrm-4-1343]), cefoxitin ([@b49-tcrm-4-1343]), cefotaxime ([@b53-tcrm-4-1343]), cefoperazone ([@b5-tcrm-4-1343]), ceftriaxone ([@b10-tcrm-4-1343]), cefaclor ([@b70-tcrm-4-1343]), and cefotetan ([@b6-tcrm-4-1343]) all decreased the numbers of anaerobic bacteria and enterobacteria. All of these drugs, except cefoperazone and ceftriaxone, also decreased the number of enterococci in most treatments. Cefotaxime decreased both enterobacteria and enterococci in one trial. Cephaloridine ([@b6-tcrm-4-1343]) and cephradine ([@b20-tcrm-4-1343]) had little effect. However, resistant bacterial strains developed as the result of administration of all of these drugs except for cephradine, ceftazidime and cef-buperazone. *C. difficile* emerged in some trials with cefepime, ceftriaxone, and cefixime. Anaerobic Gram-positive cocci increased after treatment with both ceftriaxone and cefixime ([@b60-tcrm-4-1343], [@b93-tcrm-4-1343]). The effects of other cephalosporins (cefprozil, cefpodoxime proxetil, ceftibuten, and cefadroxil) on the intestinal flora are shown in [Table 3](#t3-tcrm-4-1343){ref-type="table"}.

Cefprozil
=========

Administration of cefprozil resulted in changes in the populations of certain genera. [@b56-tcrm-4-1343] studied the effects of cefprozil in eight individuals. They administered 500 mg of cefprozil twice daily for 8 days and found that it resulted in moderate decreases in enterobacteria and slight increases in enterococci, staphylococci, and *Bacteroi-des* spp. The microbial populations were normal 4 days after treatment. The major microbiologically related consequence was soft stools. In some cases, *C. difficile* overgrowth was observed after treatment with cefprozil ([@b56-tcrm-4-1343]).

Cefpodoxime proxetil
====================

Cefpodoxime proxetil has major effects on the colonic bacteria. [@b19-tcrm-4-1343] evaluated the effects of this compound on volunteers receiving 200 mg twice a day for 7 days. The numbers of streptococci, enterobacteria, and clostridia decreased substantially in the fecal flora, and overgrowth of enterococci, yeasts and *Clostridium difficile* was observed ([@b19-tcrm-4-1343]).

Cefadroxil
==========

Administration of cefadroxil to healthy individuals does not cause measurable disturbance to the colonic ecology. [@b1-tcrm-4-1343] evaluated the effect of 500 mg cefadroxil taken for 10 days by 20 healthy volunteers. The effect on the intestinal microflora was slight and the micro-flora was normal two weeks after withdrawal of the drug.

Ceftibuten
==========

[@b18-tcrm-4-1343] administered ceftibuten to 14 healthy individuals. Each received a daily dose of 400 mg ceftibuten orally, but only two individuals had detectable levels of ceftibuten in the feces. During the administration period, the number of enterococci increased and the numbers of *E. coli* and anaerobic cocci decreased. Eight volunteers had increased levels of β-lactamases and six were colonized by *C. difficile.*

Fluoroquinolones
================

Fluoroquinolones are a class of synthetic antimicrobial agents whose effects on the ecology of colonic microflora have been intensively evaluated ([@b34-tcrm-4-1343]; [@b36-tcrm-4-1343]; [@b93-tcrm-4-1343]). By administration of different fluoroquinolones and enumeration of bacteria from different genera before and after exposure, it was shown that fluoroquinolones have a selective effect on the normal colonic bacteria. The effects of ciprofloxacin ([@b16-tcrm-4-1343]), norfloxacin ([@b28-tcrm-4-1343], [@b32-tcrm-4-1343]; [@b33-tcrm-4-1343]), ofloxacin ([@b81-tcrm-4-1343]; [@b31-tcrm-4-1343]), pefloxacin ([@b97-tcrm-4-1343]), lomefloxacin ([@b30-tcrm-4-1343]), levofloxacin ([@b38-tcrm-4-1343]), sparfloxacin ([@b87-tcrm-4-1343]), rufloxacin ([@b22-tcrm-4-1343]), sitafloxacin ([@b44-tcrm-4-1343]), gatifloxacin ([@b35-tcrm-4-1343]), trovafloxacin ([@b36-tcrm-4-1343]), and moxifloxacin ([@b36-tcrm-4-1343]; [@b29-tcrm-4-1343]) on the intestinal microflora have been analyzed. All of the fluoroquinolones tested decreased the populations of enterobacteria, and pefloxacin decreased the number of aerobic Gram-positive cocci. In general, none of the fluo-roquinolones affected the anaerobic bacterial population. Overgrowth of bacteria as the result of fluoroquinolones was not observed, but overgrowth of *Candida* was occasionally observed. Although *C. difficile* infection was not observed, the use of newer fluoroquinolones has been associated with the emergence of *C. difficile* antibiotic-associated diarrhea in some hospitals. *In vitro*, we have shown that some strains of *C. perfringens* readily become resistant to fluoroquinolones, even those that are generally effective against anaerobes ([@b86-tcrm-4-1343]). Resistant strains also exhibit physiological changes that are different from wild-type strains. Similarly, we have shown *in vitro* that one out of five strains of *C. perfringens* produced a higher amount of toxin in response to gatifloxacin exposure ([@b85-tcrm-4-1343]). The effects of some of the most recently developed fluoroquinolones (garenoxacin, gemifloxacin, and clinafloxacin) on colonic ecology have also been evaluated ([Table 4](#t4-tcrm-4-1343){ref-type="table"}).

Garenoxacin
===========

[@b75-tcrm-4-1343] evaluated the effects of oral administration of garenoxacin on the fecal microfloras of 16 individuals. Administration of 600 mg garenoxacin daily for 6 days decreased the number of enterococci, bacilli, corynebacteria, enterobacteria, bifidobacteria, lactobacilli, clostridia, and *Bacteroides* spp. in the intestinal microflora, and it increased the numbers of eubacteria. The microflora returned to normal 2 weeks after discontinuation of this broad-spectrum fluoroquinolone. The concentrations of garenoxacin in fecal samples were 14--31 mg/kg. Garenoxa-cin-resistant *Eubacterium lentum* (MIC = 64 mg/ml) was isolated from the subjects; the populations had returned to normal 14 days after discontinuation ([@b75-tcrm-4-1343]).

Gemifloxacin
============

The selective effect of gemifloxacin on the intestinal micro-flora was similar to that of other fluoroquinolones ([@b12-tcrm-4-1343]). Administration of 320 mg gemifloxacin orally for 7 days to 10 healthy subjects resulted in the suppression of enterobacteria, enterococci and streptococci. Anaerobic cocci and lactobacilli also decreased. Overgrowth or selection of resistant bacteria was not detected; the bacterial populations had returned to normal 49 days after treatment had stopped ([@b12-tcrm-4-1343]).

Clinafloxacin
=============

[@b79-tcrm-4-1343] evaluated the effects of clina-floxacin on intestinal ecology in 12 healthy individuals and found major ecological disturbances. Oral administration of 200 mg clinafloxacin for 7 days resulted in high drug levels in feces (mean value 176 mg/kg on day 7). It eradicated the aerobic bacteria in 11 of the subjects and suppressed the anaerobic microflora. Clinafloxacin-resistant *Bacteroides* sp. (MIC \> 4) also emerged; [@b79-tcrm-4-1343] recommended restricting use of this drug.

Macrolides
==========

Macrolides have a macrocyclic 14 to 16-membered lactone ring attached to a deoxy sugar. They include clarithromycin, dirithromycin, erythromycin, and roxithromycin, which have bactericidal or bacteriostatic activities. Their effects on the intestinal microflora are summarized in [Table 5](#t5-tcrm-4-1343){ref-type="table"}.

Dirithromycin
=============

[@b25-tcrm-4-1343] evaluated the impact of treatment with dirithromycin of 20 healthy individuals on the colonic microbial population. Administration of 500 mg dirithromycin daily for 7 days resulted in the detection of 12 mg/kg of dirithromycin in feces.

The numbers of enterobacteria and anaerobes (Gram-positive cocci, bifidobacteria, eubacteria, and *Bacteroides* spp.) decreased in the intestinal flora and the numbers of streptococci, staphylococci, and other anaerobes (clostridia and lactobacilli) increased. In addition, dirithromycin-resistant enterobacteria colonized the intestine. [@b25-tcrm-4-1343] concluded that dirithromycin had a significant ecological impact on the colonic bacteria.

Clarithromycin
==============

[@b26-tcrm-4-1343], [@b29-tcrm-4-1343] evaluated the ecological impact of clarithromycin in 12 volunteers. Administration of clarithromycin (500 mg twice daily for 7 days) caused significant reduction of *E. coli*, while the numbers of enterococci, enterobacters, citrobacters, klebsiellas, and pseudomonads increased markedly. No significant changes in the numbers of staphylococci, streptococci, bacilli, or *Candida* were noticed. In the anaerobic microflora, bifido-bacteria, lactobacilli and clostridia were suppressed, while no changes in peptostreptococci, *Veillonella*, *Bacteroide*s spp., or fusobacteria were found. The microflora was normal in all volunteers after 35 days. [@b26-tcrm-4-1343], [@b29-tcrm-4-1343] also found the emergence of *Bacteroides* spp. isolates that were resistant to clarithromycin after administration of 500 mg of clarithromycin for 10 days to 10 patients. These bacteria persisted for 2 weeks after the drug was discontinued. In the same study, the authors also found α-hemolytic streptococci, intestinal enterococci, and enterobacteria with resistance to clarithromycin, but no overgrowth of yeast or *C. difficile*.

A combination of 20 mg of omeprazole, 250 mg of clar-ithromycin, and 400 mg of metronidazole resulted in alteration of the normal microflora, similar to the combination of omeprazole, amoxicillin, and metronidazole ([@b2-tcrm-4-1343]). The suppression of anaerobic microflora was more pronounced than that with the amoxicillin group. Substantial increases in clarithromycin-resistant *Bacteroides* strains, from 2% to 76%, were observed during treatment. Both combinations altered the fecal microflora, but the clarithromycin combination therapy had more undesirable effects on the colonic ecosystem ([@b2-tcrm-4-1343]).

Erythromycin
============

[@b17-tcrm-4-1343] administered 1 g of eryth-romycin ethyl succinate orally for 7 days to 10 volunteers and evaluated its effect on the colonic bacteria. They found decreases in the numbers of streptococci, enterococci, and enterobacteria during administration, increases in staphylococci, and alteration of the anaerobic bacteria. In an earlier study ([@b43-tcrm-4-1343]), it had been shown that the administration of 500 mg of erythromycin twice daily for 7 days to 10 volunteers resulted in decreases in enterobacteria and most anaerobes. In addition, potentially pathogenic erythromycin-resistant enterobacteria, clostridia or yeasts colonized all subjects ([@b43-tcrm-4-1343]).

Ketolides
=========

This is a new class of compounds related to the macrolides and includes telithromycin ([@b68-tcrm-4-1343]), which differs from erythromycin in having a large aromatic side chain and substitution of sugar with a keto group. Ketolides can bind to two sites on the bacterial ribosome; therefore, they are effective even against macrolide-resistant bacteria. They also have reduced potential for inducing ketolide-resistant bacteria. [@b26-tcrm-4-1343] studied the effect of telithromycin in ten subjects and found an increase in the MIC of telithromycin for resistant *Bacteroides* spp. isolates, which persisted for 2 weeks after the drug was discontinued. However, overgrowth of yeast and *C. difficile* was not observed.

Aminoglycosides
===============

Amikacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, rhodostreptomycin, streptomycin, tobra-mycin, and apramycin are examples of aminoglycosides. [@b40-tcrm-4-1343] noted an association between administration of "intestinal antiseptics," such as oral neomycin, and superinfection by anaerobes.

Glycylcyclines
==============

Glycylcyclines, a new class of antibiotics, are tetracycline analogs developed with features to prevent either their efflux from the cells or the development of ribosomal protection proteins, which result in resistance to tetracyclines.

Tigecycline
===========

Tigecycline is a glycylcycline, which has a potent broad-spectrum activity against most Gram-positive and Gram-negative aerobic and anaerobic bacteria. Administration of 50 mg tigecycline to 20 subjects every 12 hours for 10 days ([@b77-tcrm-4-1343]) resulted in a reduction in the numbers of enterococci, *E. coli*, lactobacilli, and bifidobacteria, and increases in other enterobacteria and yeasts. Two tigecycline-resistant strains of *Klebsiella pneumoniae* and five tigecycline-resistant strains of *Enterobacter cloacae* developed ([@b77-tcrm-4-1343]).

Lincosamides
============

Lincomycin and clindamycin are lincosamides, which inhibit transpeptidase reactions by binding to the 23 S and 50 S subunits of bacterial ribosomes and inhibiting early elongation of peptide chains.

Clindamycin
===========

Clindamycin is used for the treatment not only of anaerobic infections, but also of parasitic infections, including malaria. Administration of clindamycin to 10 subjects for 7 days resulted in the disturbance of colonic ecology ([@b48-tcrm-4-1343]). Clindamycin is also associated with *C. difficile* antibiotic-associated diarrhea. [@b48-tcrm-4-1343] evaluated the effect of 600 mg of intravenous clindamycin at 8-hour intervals for 48 hours, which resulted in the decrease of enterococci, streptococci, and anaerobic bacteria. After treatment, streptococci and anaerobic bacteria proliferated; postoperative infection due to *Enterococcus faecalis* occurred in some of the patients.

Oxazolidones
============

Linezolid belongs to the class of antimicrobial agents called oxazolidones. It is a synthetic antibiotic, rarely used because of its high price, but it is effective for the treatment of mul-tidrug-resistant bacterial infections, including those caused by *Streptococcus* spp. and MRSA. Administration of 600 mg of linezolid for 7 days to healthy volunteers resulted in the suppression of enterococci and increases in the numbers of *Klebsiella* spp. It also decreased the numbers of the following anaerobes: bifidobacteria, lactobacilli, clostridia, and *Bacte-roides* spp. Thirty-five days after termination of treatment, the microflora was normal ([@b57-tcrm-4-1343]).

Glycopeptides
=============

This class consists of glycosylated cyclic nonribosomal peptides and includes vancomycin, teicoplanin, telavancin, tramplanin, decaplanin, and dalbavancin, which is a lipogly-copeptide. They inhibit peptidoglycan synthesis.

Vancomycin
==========

This drug has been used as the last resort for treatment of infections caused by Gram-positive bacteria. [@b27-tcrm-4-1343] evaluated the effects of vancomycin in 10 individuals after treatment with 250 mg of cefuroxime axetil twice daily for 7 days. The subjects then received 125 mg of vancomycin four times daily for 7 days. The authors concluded that vancomycin causes ecological disturbances of the intestinal microflora. Vancomycin treatment resulted in decreases in the numbers of *Enterococcus faecium*, *E. faecalis*, and *E. durans* and of anaerobes, including bifidobacteria and *Bacteroides* spp. It also resulted in the emergence of motile enterococci, including *E. gallinarum* and *E. casseliflavus* strains with decreased susceptibility to vancomycin (MIC = 4--16 mg/ml). Some of these strains had the *van*C2 (C3) gene. In addition, vancomycin-resistant strains of *Pediococcus*, *Lactobacillus*, *Klebsiella*, *Citrobacter*, and *Enterobacter* species also emerged. Recently, other investigators have shown that oral vancomycin promotes the overgrowth of vancomycin-resistant enterococci ([@b3-tcrm-4-1343]).

Dalbavancin
===========

This is a novel lipoglycopeptide, related to vancomycin, and similarly to that drug it is used for treatment of MRSA and *S. epidermidis*. [@b76-tcrm-4-1343] evaluated the effect of this drug in 12 individuals. When 1 g dalbavancin was given to six men and six women, there were some changes in numbers of enterococci and *E. coli* but no changes in numbers of lactobacilli, clostridia, and *Bacteroides* spp. No *C. difficile* strains were recovered. No newly colonizing aerobic or anaerobic bacteria with resistance to dalbavancin were found. Dalbavancin apparently has no major ecological effects on the normal human intestinal microflora ([@b12-tcrm-4-1343], [@b76-tcrm-4-1343]).

Metronidazole
=============

Metronidazole is used for the treatment of anaerobic bacterial infections and is also used in combination with other drugs for treatment of ulcerative colitis. It has been shown to eliminate methanogenic Archaea ([@b7-tcrm-4-1343]). Use of oral metronidazole for the treatment of *C. difficile-*associated disease has resulted in the overgrowth of enterococci, including vancomycin-resistant strains ([@b3-tcrm-4-1343]).

Conclusions
===========

The colonic microflora provides a number of benefits, including contributing to the host's nutrition and protecting the host from infection. In most cases of antimicrobial therapy, the bacterial populations in some genera are reduced in numbers while those in other genera increase. In some cases, the increased numbers of certain bacteria are accompanied by resistant strains of bacteria or overgrowth by fungi. Treatment with antimicrobial combinations does not necessarily prevent resistance development. It may even result in fungal overgrowth and appearance of bacteria with resistance to all of the drugs in the combination. Examples are the amoxicillin and metronidazole combination and the aztreonam combination with either tobramycin or cloxacillin, all of which result not only in the suppression of anaerobes but also in the overgrowth of fungi. Some of the anaerobic bacteria may keep the fungi in check. A review of the impact of antimicrobial agents on colonic ecology also shows variation among individuals in response to treatment with these drugs and variation in the effects of these drugs on different strains of the same bacterium. Toxin-producing strains of *C. difficile* have been found in some hospitals after fluoroquinolone therapy, and some strains of *C. perfringens* produce toxin after gatifloxacin exposure. The importance of judicious use of these important drugs cannot be overemphasized.

We extend special thanks to Dr Carl E. Nord and Dr Kidon Sung for reviewing this manuscript. The views presented in this article do not necessarily reflect those of the US Food and Drug Administration.

###### 

Effects of penicillins, alone or in combination with other drugs, on intestinal microflora

  Compound                          Bacteria suppressed                                   Bacteria proliferated      Overgrowth                            Reference
  --------------------------------- ----------------------------------------------------- -------------------------- ------------------------------------- --------------------
  Ampicillin                        Enterobacteria, enterococci, and anaerobic bacteria                              *Candida* in some                     [@b54-tcrm-4-1343]
  Ampicillin and sulbactam          Enterobacteria, enterococci, and anaerobic bacteria                              *Candida* or *C. difficile* in some   [@b49-tcrm-4-1343]
  Piperacillin                      Enterobacteria, enterococci, and anaerobic bacteria                              *Candida* or *C. difficile* in some   [@b50-tcrm-4-1343]
  Amoxicillin                       Enterobacteria                                        Resistant enterobacteria   *Candida* or *C. difficile* in some   [@b42-tcrm-4-1343]
  Ticarcillin and clavulanic acid   Enterococci                                                                      *Candida* or *C. difficile* in some   [@b64-tcrm-4-1343]
  Phenoxymethylpenicillin           Little effect                                                                                                          [@b1-tcrm-4-1343]

###### 

Effects of selected β-lactams other than cephalosporins, including those in combination with other drugs, on intestinal microflora

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound                               Treatment (mg per day)   Number of days and number of treatments per day   Number of subjects                Bacteria suppressed                             Bacteria proliferated        Resistant strains developed or other results                                                  Days to normal after treatment discontinued   Reference
  -------------------------------------- ------------------------ ------------------------------------------------- --------------------------------- ----------------------------------------------- ---------------------------- --------------------------------------------------------------------------------------------- --------------------------------------------- ----------------------------------------
  Piperacillin/tazobactam                4000/500                 4--8                                              20                                Enterobacteria\                                                                                                                                                                                                          [@b66-tcrm-4-1343]
                                                                                                                                                      Enterococci\                                                                                                                                                                                                             
                                                                                                                                                      Bifidobacteria\                                                                                                                                                                                                          
                                                                                                                                                      Eubacteria\                                                                                                                                                                                                              
                                                                                                                                                      Lactobacilli\                                                                                                                                                                                                            
                                                                                                                                                      Clostridia\                                                                                                                                                                                                              
                                                                                                                                                      Gram-positive cocci                                                                                                                                                                                                      

  Omeprazole/amoxicillin                 20/1000                  14/2                                              14                                Alteration in microflora                                                     Enterobacterial β-lactamase production                                                                                                      [@b91-tcrm-4-1343]

  Amoxicillin/clavulanic acid            1000                     7                                                 12                                Bifidobacteria\                                 Enterococci\                 *Clostridium difficile* isolated from three volunteers                                                                                      [@b57-tcrm-4-1343]
                                                                                                                                                      Lactobacilli\                                   *Escherichia coli*                                                                                                                                                       
                                                                                                                                                      Clostridia                                                                                                                                                                                                               

  Amoxicillin                            500                      7/3                                               10                                                                                                             Amoxicillin-resistant bacteria, including *E. coli*, *Klebsiella* and *Enterobacter*                                                        [@b18-tcrm-4-1343], [@b19-tcrm-4-1343]

  Omeprazole/amoxicillin/metronidazole   20/1000/40               7/2                                               14                                Marked changes                                  Total anaerobic microflora   *Streptococcus* spp. *Enterococcus* spp. Enterobacteria Yeast colonization in nine subjects   35 days                                       [@b2-tcrm-4-1343]

  Imipenem (surgical prophylaxis)        500/1000                 2/4                                               20                                Staphylococci\                                                                                                                                                             No colonization; normal after 14 days         [@b46-tcrm-4-1343]
                                                                                                                                                      Streptococci Enterococci\                                                                                                                                                                                                
                                                                                                                                                      Enterobacteria\                                                                                                                                                                                                          
                                                                                                                                                      Anaerobic cocci\                                                                                                                                                                                                         
                                                                                                                                                      BifidobacteriaEubacteria\                                                                                                                                                                                                
                                                                                                                                                      Lactobacilli\                                                                                                                                                                                                            
                                                                                                                                                      Clostridia Fusobacteria\                                                                                                                                                                                                 
                                                                                                                                                      *Bacteroides*                                                                                                                                                                                                            

  Pivmecillinam                          400                      14--41                                            15                                                                                *E. coli*                                                                                                                                                                [@b94-tcrm-4-1343]

  Ertapenem                              1000                     7                                                 10                                Lactobacilli\                                   Enterococci                  Overgrowth of yeast                                                                           21--35 days                                   [@b82-tcrm-4-1343]
                                                                                                                                                      Bifidobacteria\                                                                                                                                                                                                          
                                                                                                                                                      Clostridia *Bacteroides*\                                                                                                                                                                                                
                                                                                                                                                      *E. coli*                                                                                                                                                                                                                

  Aztreonam plus tobramycin                                                                                         15 febrile neutropenic patients   Enteric Gram-negative bacilli Fecal anaerobes                                Fungal contamination                                                                                                                        [@b58-tcrm-4-1343]

  Aztreonam plus cloxacillin                                                                                        14 febrile neutropenic patients   Enteric Gram-negative bacilli Fecal anaerobes                                Fungal contamination                                                                                                                        [@b58-tcrm-4-1343]

  Moxalactam plus tobramycin                                                                                                                          Enteric Gram-negative bacilli Fecal anaerobes                                Fungal contamination                                                                                                                        [@b58-tcrm-4-1343]

  Imipenem                               500--1000                4--11/4                                           10                                Enterobacteria Anaero-bic cocci *Bacteroides*                                                                                                                                                                            [@b46-tcrm-4-1343]

  Meropenem                              500                      7/3                                               10                                Enterobacteria\                                 Enterococci                                                                                                                14 days                                       [@b14-tcrm-4-1343]
                                                                                                                                                      Streptococci\                                                                                                                                                                                                            
                                                                                                                                                      Clostridia\                                                                                                                                                                                                              
                                                                                                                                                      *Bacteroides*\                                                                                                                                                                                                           
                                                                                                                                                      Gram-negative cocci                                                                                                                                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Effects of cephalosporins on intestinal microflora

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound               Treatment (mg per day)   Number of days and number of treatments per day   Number of subjects   Bacteria suppressed         Bacteria proliferated                 Resistant strains developed or other side effects                      Days to normal after treatment discontinued   Reference
  ---------------------- ------------------------ ------------------------------------------------- -------------------- --------------------------- ------------------------------------- ---------------------------------------------------------------------- --------------------------------------------- --------------------
  Cefprozil              500                      8/2                                               8                    Enterobacteria              Enterococci\                          Soft stools                                                            4 days                                        [@b56-tcrm-4-1343]
                                                                                                                                                     Staphylococci\                                                                                                                                             
                                                                                                                                                     *Bacteroides*                                                                                                                                              

  Cefadroxil             500                      10                                                20                   Not much change             Not much change                                                                                                                                            [@b1-tcrm-4-1343]

  Cefpodoxime proxetil   200                      7/2                                               10                   Streptococci\               Enterococci *Clostridium difficile*   β-Lactamase activity in the flora of some subjects                                                                   [@b19-tcrm-4-1343]
                                                                                                                         Enterobacteria Clostridia                                                                                                                                                              

  Ceftriaxone            2000                     7                                                 10                   Lactobacilli\               Enterococci                           Overgrowth of yeast                                                    1 to 35 days                                  [@b82-tcrm-4-1343]
                                                                                                                         Bifidobacteria\                                                                                                                                                                        
                                                                                                                         Clostridia *Bacteroides*\                                                                                                                                                              
                                                                                                                         *E. coli*                                                                                                                                                                              

  Ceftibutan             400                      10                                                14                   Enterococci                 *E. coli* and anaerobic cocci         Increased β-lactamase *C. difficile* colonization in six individuals                                                 [@b18-tcrm-4-1343]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Effects of fluoroquinolones on intestinal microflora

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound        Treatment (mg per day)   Number of days   Number of subjects   Bacteria suppressed   Bacteria proliferated   Resistant strains developed   Days to normal after treatment discontinued   Reference
  --------------- ------------------------ ---------------- -------------------- --------------------- ----------------------- ----------------------------- --------------------------------------------- --------------------
  Garenoxacin     600                      6                16                   Enterococci\          Eubacteria              Garenoxacin-resistant\        14 days                                       [@b75-tcrm-4-1343]
                                                                                 Bacilli\                                      *Eubacterium lentum*                                                        
                                                                                 Corynebacteria\                                                                                                           
                                                                                 Enterobacteria\                                                                                                           
                                                                                 Bifidobacteria\                                                                                                           
                                                                                 Lactobacilli\                                                                                                             
                                                                                 Clostridia\                                                                                                               
                                                                                 *Bacteroides*                                                                                                             

  Gemifloxacin    320                      7                10                   Enterobacteria\                                                             49 days                                       [@b12-tcrm-4-1343]
                                                                                 Enterococci\                                                                                                              
                                                                                 Streptococci\                                                                                                             
                                                                                 Anaerobic cocci\                                                                                                          
                                                                                 Lactobacilli                                                                                                              

  Clinafloxacin   200                      7                12                   Aerobic bacteria      Anaerobic bacteria      *Bacteroides* spp.                                                          [@b79-tcrm-4-1343]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Effects of dirithromycin, clarithromycin, tigecycline, and erythromycin on intestinal microflora

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound                                  Treatment (mg per day)   Number of days and number of treatments per day   Number of subjects   Bacteria suppressed             Bacteria and yeasts proliferated   Resistant strains developed                                  Days to normal after treatment discontinued   Reference
  ----------------------------------------- ------------------------ ------------------------------------------------- -------------------- ------------------------------- ---------------------------------- ------------------------------------------------------------ --------------------------------------------- --------------------
  Dirithromycin                             500                      7                                                 20                   Enterobacteria Anaerobes\       Streptococci\                      Dirithromycin-resistant enterobacteria                                                                     [@b25-tcrm-4-1343]
                                                                                                                                            Gram-positive cocci\            Staphylococci\                                                                                                                                
                                                                                                                                            Bifidobacteria\                 Anaerobes\                                                                                                                                    
                                                                                                                                            Eubacteria *Bacteroides* spp.   Clostridia\                                                                                                                                   
                                                                                                                                                                            Lactobacilli                                                                                                                                  

  Clarithromycin                            500                      7/2                                               12                   *Escherichia coli*\             Enterococci\                       None                                                         35 days                                       [@b26-tcrm-4-1343]
                                                                                                                                            Bifidobacteria Lactobacilli\    *Enterobacter*\                                                                                                                               
                                                                                                                                            Clostridia                      *Citrobacter*\                                                                                                                                
                                                                                                                                                                            *Klebsiella*\                                                                                                                                 
                                                                                                                                                                            *Pseudomonas*                                                                                                                                 

  Omeprazole/clarithromycin/metronidazole   20/250/400               7                                                 16                   Anaerobic bacteria              Total anaerobic microflora         *Streptococcus* spp.\                                                                                      [@b2-tcrm-4-1343]
                                                                                                                                                                                                               *Enterococcus* spp.\                                                                                       
                                                                                                                                                                                                               Enterobacteria\                                                                                            
                                                                                                                                                                                                               Clarithromycin-resistant\                                                                                  
                                                                                                                                                                                                               *Bacteroides* spp.                                                                                         

  Tigecycline                               100/then 50/2            10                                                13                   Enterococci *Escherichia*\      Enterobacteria and yeasts          *Klebsiella pneumoniae*\                                                                                   [@b77-tcrm-4-1343]
                                                                                                                                            Lactobacilli Bifidobacteria                                        Five resistant *Enterobacter cloacae* strains                                                              

  Erythromycin                              1000/500                 7/2                                               10                   Streptococci\                   *Staphylococcus* spp.              Erythromycin-resistant enterobacteria, clostridia or yeast                                                 [@b17-tcrm-4-1343]
                                                                                                                                            Enterococci Enterobacteria\                                                                                                                                                   
                                                                                                                                            Anaerobic bacteria were also\                                                                                                                                                 
                                                                                                                                            affected                                                                                                                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
